[EN] SUBSTITUTED QUINAZOLINES AS FUNGICIDES<br/>[FR] QUINAZOLINES SUBSTITUÉES, UTILISÉES EN TANT QUE FONGICIDES
申请人:SYNGENTA PARTICIPATIONS AG
公开号:WO2010136475A1
公开(公告)日:2010-12-02
The present invention relates to a compound of formula (I) wherein wherein the substituents have the definitions as defined in claim 1or a salt or a N-oxide thereof, their use and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.
The present invention relates to a compound of formula (I) wherein the substituents have the definitions as defined in claim
1
or a salt or a N-oxide thereof, their use and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.
[EN] PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION<br/>[FR] PIPÉRAZINE UTILISÉE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS AGISSANT SUR LE RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE DE TYPE 5 (MGLUR5)
申请人:WYETH CORP
公开号:WO2009143404A1
公开(公告)日:2009-11-26
The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula (I); wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.
Catalytic Alkyne Arylation Using Traceless Directing Groups
作者:Jung‐Woo Park、Bubwoong Kang、Vy M. Dong
DOI:10.1002/anie.201804955
日期:2018.10.8
to generate enamines, which are then hydrolyzed to either α‐arylphenones or α,α‐diarylketones. This Pd‐catalyzed method overcomes established known pathways to enable the use of amines as tracelessdirectinggroups for C−C bond formation.
The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I:
wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.